Xcout Intel
Focal Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Focal Therapeutics, Inc. among medical device companies — ranked by similarity to what Focal Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Focal Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Focal Therapeutics, Inc.
Focal Therapeutics provides the Focal One robotic system, which utilizes high-intensity focused ultrasound (HIFU) technology to non-invasively target and ablate prostate tissue for prostate cancer patients. The system is designed for urologists to precisely treat targeted lesions while sparing healthy surrounding tissue and minimizing side effects.
Focal Therapeutics, Inc. at a glance
Focal Therapeutics, Inc. is a medical device company headquartered in United States. It has raised at least $11M across the 3 funding rounds on record. Its most recent funding round raised $48,880 in July 2016.
Focal Therapeutics, Inc. funding rounds
At least $11M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $48,880 | — | |
| SEC Form D filing | $3.8M | — | |
| Series A | $7.1M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Focal Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Focal Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar medical device company
Focal Medical develops and manufactures the Focal One HIFU Robotic System, a non-invasive medical device that utilizes high-intensity focused ultrasound technology to precisely target and ablate prostate tissue. The company serves urologists and healthcare facilities by providing equipment for prostate cancer management that preserves healthy surrounding tissue and minimizes side effects for patients.
Medical Devices
SpectraCure is a medical technology company that develops a precision treatment system for localized prostate cancer and other internal solid tumors. The company utilizes photodynamic therapy (PDT) combined with a proprietary dose-planning platform to offer targeted, minimally invasive treatments for prostate cancer patients.
Medical - Devices
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Medical Devices
URO-1, Inc. is a privately held medical device company established in 2017 and based in Greensboro, North Carolina. The company develops and manufactures surgical solutions and instruments for biopsy procedures, specifically focusing on prostate and soft tissue cancer diagnostics.
Medical Devices
Francis Medical, Inc. develops medical technology for targeted tissue ablation, including the Vanquish System designed for water vapor prostate treatment.
Medical Devices
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Medical Devices
Current Surgical Inc. is developing a digital surgery platform that combines real-time imaging, focused ultrasound, and AI-driven algorithms to provide millimeter-level precision for treating solid tumors and other medical conditions. The platform aims to assist surgeons by enhancing accuracy and reducing risk in minimally invasive procedures across multiple markets such as oncology, cardiology, and neurology.
Medical Devices
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Medical Devices
MedicaMetrix develops medical devices for prostate health, specifically offering the ProstaMetrix platform to measure prostate volume and calculate Prostate Specific Antigen Density (PSAD) during routine clinical examinations. The company serves urologists and healthcare professionals by providing tools for the early detection and ongoing monitoring of prostate conditions such as prostate cancer and BPH.
Medical Devices
Accuray Incorporated designs and manufactures radiotherapy and radiosurgery treatment systems, such as the CyberKnife and Radixact platforms, to deliver precise radiation therapy for cancer care. The company serves clinicians and healthcare providers globally, aiming to expand the curative power of radiation treatment for complex and routine patient needs.
Medical Devices
3DBiopsy, Inc. operates as a medical device company that develops 3D mapping software, biopsy needles, biopsy actuators, and integrated pathology systems.
Medical Devices
Theraclion develops non-invasive, robotic medical devices that utilize high-intensity focused ultrasound (HIFU) for extracorporeal surgery. Its primary products include the SONOVEIN system for treating varicose veins and the ECHOPULSE system for treating thyroid nodules and breast fibroadenomas.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Focal Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Focal Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →